



Exer - Torrance
 2613 Pacific Coast Highway
 Torrance, CA 90505
 Phone: 424-625-0220

Name: Kashiwao, Kotaro	DOB: 12/22/2015	Sex: M
Acct #: f879056c176520	MR #: 1d2a3b68a8645a3	AGE: 6
Visit Date: 01/15/2022 12:56	Bed #:	
Treating Provider: Mai Lai MD		
Patient's PMD: Naoko Matsumoto 310-483-7880		

TEST RESULTS

RESULTS FROM OUTSIDE LAB STUDIES:

REPORT 1

LAB SOURCE

Patient name: Kashiwao, Kotaro
 Results from: Exer with Providence: EXER Urgent Care Address: 8985 Venice Blvd. STE A3B Culver City CA 90034
 Medical Director: Dr. Don Xu, MD, Ph.D.
 Ordered by: Lai, Mai
 Date of Report: 01/15/2022 13:19:00
 Specimen ID: f879056c176520
 Date Ordered: 01/15/2022 13:19:00
 Date Received: 01/15/2022 13:19:00
 Report Status: CM

SARS-CoV-2

-- SARS-CoV-2 Positive (NL = Negative) *** F
 The test performed at EXER-PCR laboratory for the SARS-CoV-2 identification is intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab samples (Nasal swabs acceptable) from patients who meet COVID-19 clinical and/or epidemiological criteria. Testing methodology is real-time RT-PCR. LumiraDx SARS-CoV-2 RNA STAR used here, has been designed to minimize the likelihood of false positive test results. However, in the case it happens the risks should be acknowledged. LumiraDx SARS-CoV-2 RNA STAR Complete has been designed to detect a region in ORF1a from nucleic acid sequences within the genome of the SARS-CoV-2 RNA. A positive test result for COVID-19 indicates that RNA from SARS-CoV-2 was detected, and the patient is infected with the virus and presumed to be contagious. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions. Patient management decisions should be made with a healthcare provider and follow current CDC guidelines.
 Risks to patients due to a false positive result could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 patients, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.
 In general, test results must be correlated with clinical presentation and other laboratory data. Test performance can be affected by specimen type, collection time during the course of infection, and concentration of viral RNA. This test has received Emergency Authorization for use by FDA. The EUA for this test is supported by the Secretary of Health and Human Service's (HHS's) declaration (under Section 564 (b) (1) of the of the Act, 21 U.S.C. section 360bbb-3(b) (1).
 EXER-PCR Laboratory is CLIA certified laboratory. CLIA# 05D1082684, located in 8985 Venice Blvd. Culver City, CA 90034, under the directorship of Dr. Don Xu, MD, Ph.D. (Laboratory Director), Dr. K. McCabe, DO, FACEP (Clinical Consultant), and Dr. J. Kermani MSCLS; Ph.D. (Technical Supervisor).

REPORT 2

Influenza A

-- Influenza A Negative (NL = Negative) F

